Sentiment-Signal
13,8
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Unternehmen & Branche
| Name | Forte Biosciences, Inc. |
|---|---|
| Ticker | FBRX |
| CIK | 0001419041 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 349626208 |
|---|---|
| ISIN | US3496262086 |
| Typ | Common Stock |
| Marktkapitalisierung | 385,9 Mio. USD |
| Beta | 3,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -69,375,000 | -4.71 | 82,779,000 | 60,991,000 | |
| 2025-09-30 | 10-Q | -17,682,000 | -0.99 | 97,089,000 | 84,097,000 | |
| 2025-06-30 | 10-Q | -11,249,000 | -0.96 | 107,783,000 | 98,613,000 | |
| 2025-03-31 | 10-Q | -15,656,000 | -1.37 | 47,459,000 | 38,427,000 | |
| 2024-12-31 | 10-K | -35,478,000 | -12.17 | 61,561,000 | 52,480,000 | |
| 2024-09-30 | 10-Q | -8,392,000 | -4.54 | 17,946,000 | 9,366,000 | |
| 2024-06-30 | 10-Q | -12,511,000 | -6.78 | 26,078,000 | 16,961,000 | |
| 2024-03-31 | 10-Q | -7,420,000 | -4.03 | 32,017,000 | 28,685,000 | |
| 2023-12-31 | 10-K | -31,476,000 | -24.92 | 38,980,000 | 35,314,000 | |
| 2023-09-30 | 10-Q | -9,955,000 | -6.57 | 47,879,000 | 40,408,000 | |
| 2023-06-30 | 10-Q | -8,896,000 | -0.42 | 31,184,000 | 24,884,000 | |
| 2023-03-31 | 10-Q | -6,753,000 | -0.32 | 36,708,000 | 32,948,000 | |
| 2022-12-31 | 10-K | -13,879,000 | -0.80 | 41,997,000 | 38,818,000 | |
| 2022-09-30 | 10-Q | -3,400,000 | -0.18 | 45,128,000 | 42,835,000 | |
| 2022-06-30 | 10-Q | -3,035,000 | -0.21 | 39,720,000 | 38,207,000 | |
| 2022-03-31 | 10-Q | -2,567,000 | -0.17 | 41,304,000 | 40,048,000 | |
| 2021-12-31 | 10-K | -21,708,000 | -1.55 | 43,306,000 | 41,548,000 | |
| 2021-09-30 | 10-Q | -7,751,000 | -0.54 | 47,390,000 | 43,650,000 | |
| 2021-06-30 | 10-Q | -5,812,000 | -0.43 | 52,887,000 | 49,909,000 | |
| 2021-03-31 | 10-Q | -4,804,000 | 57,068,000 | 54,698,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-30 | Riley Antony A | Officer, CHIEF FINANCIAL OFFICER | Open Market Purchase | 9,680 | 26.33 | 254,832.78 | +100,0% |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 30.06.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| AWM Investment Company, Inc. | 261,821 | 3,385,346 | 100.00 |